Axela, Inc. Launches dotLabTM System in Europe
Novel System Advances Capabilities for Protein Research
TORONTO–Axela Inc., a recognized innovator in protein interaction technology, announced the introduction of the dotLab™ System in Europe at Analytica 2008, being held in Munich, Germany, April 1-4, 2008. The system, successfully introduced in North America in 2007, is now being used by life scientists in the academic, pharmaceutical, biotechnology and clinical research fields to exploit interactions between a protein target and other biomolecules.
Chosen by Frost and Sullivan as the Protein Assay Product of the Year for 2007, the dotLab System brings real-time monitoring to the study of protein interactions, expression, immunoassay development, and routine quantitation. This eliminates the time and cost of platform transitions associated with conventional approaches.
The presentation at Analytica, Understanding Interactions Enables Real-Time Immunoassays, will be given by Paul Smith, VP Research Markets in the Innovations and Technology Forum on April 3, 2008, Hall A3, 384/I, 13:00 – 13:30. The dotLab system will be on display in Hall A3, Booth 276.
“We are excited to have achieved this milestone in Axela’s corporate growth,” says Rocky Ganske, Axela President and CEO. “Existing users quickly demonstrated how understanding interactions can improve protein detection and quantitation. Simultaneously measuring low and high abundance proteins and interrogating complexes directly in biological samples enables significant new applications.”
Axela’s European Sales and Support Office will be located in Bemmel, The Netherlands and managed by TouchDown Biomarketing B.V. This highly experienced team provides local scientific and technical support and is backed by extensive consumable and reagent distribution capability.
About Axela, Inc.
Axela has developed a proprietary technology for real-time protein detection, characterization, and monitoring directly in biological samples. The company’s products provide simple tools and reagents to life science and clinical researchers to study interactions, expand the utility of traditional immunoassays and access novel categories of diagnostic markers. Participating in the research market provides unique access to novel discoveries that form the basis of a growing content pipeline for future multiplex diagnostic offerings. Axela is a privately-held company with operations in Toronto and California whose major investor is VenGrowth Private Equity Partners Inc., one of Canada’s premier private equity managers.